# Clinical Trials Data KIT - Document 3

# NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.

## Clinical Trial: https://clinicaltrials.gov/study/NCT00318266

"eligibilityCriteria": "Inclusion Criteria:\n\n\* \u00b7 History of pTis, pT1, large (\\>2cm) pTa or multiple pTa bladder cancer tumours.\n\nWritten Informed Consent prior to any study-related procedures.\n\nExclusion Criteria:\n\n\* History of bladder cancer tumours other than those listed in inclusion",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patient with a history og pTis, pT1, larger ( \\>2 cm) pTa or multiple pTa bladder tumors.",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
This trial is specifically for certain types of bladder cancer. The criteria mention nothing about KIT gene mutations, so having one would not automatically exclude a patient. Eligibility depends entirely on the patient's bladder cancer staging (pTis, pT1, large pTa, or multiple pTa). If they meet the inclusion criteria based on their tumor characteristics \*and\* do not fall under the exclusion criteria (having other types of bladder cancer), then they \*could\* be eligible, regardless of their KIT gene mutation status.